CN112694471B - 一种苯并吲哚盐-吩噻嗪衍生物及其制备和应用 - Google Patents
一种苯并吲哚盐-吩噻嗪衍生物及其制备和应用 Download PDFInfo
- Publication number
- CN112694471B CN112694471B CN202110150987.5A CN202110150987A CN112694471B CN 112694471 B CN112694471 B CN 112694471B CN 202110150987 A CN202110150987 A CN 202110150987A CN 112694471 B CN112694471 B CN 112694471B
- Authority
- CN
- China
- Prior art keywords
- phenothiazine
- salt
- hclo
- reaction
- benzindole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title abstract description 6
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims abstract description 67
- GHQSQIFLJGZVFA-UHFFFAOYSA-N C1=CC=CC=2SC3=CC=CC=C3NC12.N1C=CC2=CC=C3C(=C12)C=CC=C3 Chemical class C1=CC=CC=2SC3=CC=CC=C3NC12.N1C=CC2=CC=C3C(=C12)C=CC=C3 GHQSQIFLJGZVFA-UHFFFAOYSA-N 0.000 claims abstract description 42
- 238000006243 chemical reaction Methods 0.000 claims abstract description 35
- 238000001514 detection method Methods 0.000 claims abstract description 29
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229950000688 phenothiazine Drugs 0.000 claims abstract description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 29
- 239000000872 buffer Substances 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 14
- 238000004440 column chromatography Methods 0.000 claims description 12
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 10
- BPMJEQGEJQHGCZ-UHFFFAOYSA-N 10-butylphenothiazine-3-carbaldehyde Chemical compound O=CC1=CC=C2N(CCCC)C3=CC=CC=C3SC2=C1 BPMJEQGEJQHGCZ-UHFFFAOYSA-N 0.000 claims description 9
- ROSJCZCZPCVEPI-UHFFFAOYSA-N 10-butylphenothiazine Chemical compound C1=CC=C2N(CCCC)C3=CC=CC=C3SC2=C1 ROSJCZCZPCVEPI-UHFFFAOYSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- 239000005457 ice water Substances 0.000 claims description 6
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 6
- 239000012074 organic phase Substances 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 claims description 6
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 claims description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 5
- 239000012312 sodium hydride Substances 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 239000012300 argon atmosphere Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000010791 quenching Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 241000252212 Danio rerio Species 0.000 abstract description 14
- 239000007850 fluorescent dye Substances 0.000 abstract description 10
- 239000000523 sample Substances 0.000 abstract description 10
- HIYWOHBEPVGIQN-UHFFFAOYSA-N 1h-benzo[g]indole Chemical class C1=CC=CC2=C(NC=C3)C3=CC=C21 HIYWOHBEPVGIQN-UHFFFAOYSA-N 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000012544 monitoring process Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 238000001917 fluorescence detection Methods 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 238000006073 displacement reaction Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 27
- 238000011534 incubation Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000002189 fluorescence spectrum Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000004769 mitochondrial stress Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940066767 systemic antihistamines phenothiazine derivative Drugs 0.000 description 3
- RUVJFMSQTCEAAB-UHFFFAOYSA-M 2-[3-[5,6-dichloro-1,3-bis[[4-(chloromethyl)phenyl]methyl]benzimidazol-2-ylidene]prop-1-enyl]-3-methyl-1,3-benzoxazol-3-ium;chloride Chemical compound [Cl-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C(N(C1=CC(Cl)=C(Cl)C=C11)CC=2C=CC(CCl)=CC=2)N1CC1=CC=C(CCl)C=C1 RUVJFMSQTCEAAB-UHFFFAOYSA-M 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000008846 dynamic interplay Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- -1 2- (10-n-butyl-phenothiazin 3-yl) vinyl Chemical group 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003462 sulfoxides Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
- G01N21/6458—Fluorescence microscopy
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
- C09K2211/1037—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with sulfur
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明提供了一种苯并吲哚盐‑吩噻嗪衍生物及其制备和应用。本发明提供的苯并吲哚盐‑吩噻嗪衍生物合成便捷,由便宜易得的原料吩噻嗪和苯并吲哚衍生物经四步反应得到,该苯并吲哚盐‑吩噻嗪衍生物具有双反应位点、检测灵敏度高和斯托克斯位移大的优势,对HClO和SO2的检测具有高度的选择性,且两者的荧光检测信号互不干扰。该分子不仅能够监测细胞内的HClO和SO2,同时能够监测HClO和SO2诱导的线粒体应激以及两者间的动力学平衡,该探针还实现了监测斑马鱼体内HClO和SO2的动力学相互作用,并阐明了细胞水平和斑马鱼体内HClO和SO2所扮演的生理角色。因此,该苯并吲哚盐‑吩噻嗪衍生物对相关疾病的诊断和治疗具有重要意义。
Description
技术领域
本发明属于有机小分子荧光探针和生物传感技术领域,具体涉及一种苯并吲哚盐-吩噻嗪衍生物及其制备方法,本发明还涉及苯并吲哚盐-吩噻嗪衍生物在水相体系中检测HClO的应用以及在水相体系中检测检测SO2的应用;本发明同时还涉及苯并吲哚盐-吩噻嗪衍生物在细胞中检测HClO的应用以及在细胞中检测SO2的应用。
背景技术
次氯酸(HClO)作为体内最重要的活性氧之一,主要由髓过氧化物酶催化氯离子的过氧化反应产生。依赖于其在胞内的浓度,HClO在生命系统中既可作为免疫系统的调节剂,表现出抗菌,促炎和抗炎等特性;也可作为毒性分子诱发细胞的氧化应激,导致脂质、蛋白质和生物大分子的氧化损伤以及一系列疾病的发生,如心血管疾病、关节炎,神经元退行性病变和癌症等。为了防御活性氧(如HClO)诱发的潜在的氧化损伤,生物体利用抗氧化剂(如活性硫)建立了保护性免疫机制。其中二氧化硫(SO2)作为最重要的活性硫之一,它在胞内主要通过催化氧化含硫氨基酸和硫化氢内源性地产生,作为继NO,CO和H2S之后的另一内源性气体信使分子,它在维持生物体的氧化还原平衡中起着十分重要的作用;同时,SO2水平的异常与癌症、神经系统的紊乱和心血管疾病有着密不可分的关系。作为体内最重要的活性氧和活性硫,HClO和SO2在调控机体正常的生理功能和信号传导以及维持其氧化还原稳态等方面起着重要作用,它们在生理环境中不仅扮演着“双刃剑”的角色且彼此紧密相关。因此,探究HClO和SO2的动力学相互作用,将为研究它们的生理功能提供更为精准的信息,同时对相关疾病的诊断和治疗具有重要意义。
目前能够实现对HClO和SO2同时检测的荧光探针非常有限(J. Mater. Chem. B,2017, 5,8389-8398; Talanta, 2017, 165, 625-631; Biomaterials, 2017, 133, 82-93;Chem. Commun., 2020, 56, 7710-7713),而且这些探针都存在一些缺陷,如利用单一反应位点同时识别HClO和SO2,该类探针会因竞争反应导致检测结果出现误差;响应时间较长且荧光检测信号相互干扰等。针对以上存在的问题,设计合成双反应位点、选择性高、灵敏性好且具有大波长位移的荧光探针,用于同时检测HClO和SO2以及它们之间的动力学相互作用,并澄清各自的生理角色,是当前荧光探针和生物传感技术领域的热点和难点。
发明内容
针对现有技术的不足,本发明提供了的目的是一种苯并吲哚盐-吩噻嗪衍生物及其制备方法;
本发明的另一个目的是提供苯并吲哚盐-吩噻嗪衍生物在水相体系中检测HClO的应用;
本发明的再一个目的是提供苯并吲哚盐-吩噻嗪衍生物在水相体系中检测SO2的应用;
本发明的还有一个目的是提供苯并吲哚盐-吩噻嗪衍生物在细胞中检测HClO的应用;
本发明的更一个目的是提供苯并吲哚盐-吩噻嗪衍生物在细胞中检测SO2的应用。
一、苯并吲哚盐-吩噻嗪衍生物及其制备
本发明提供的苯并吲哚盐-吩噻嗪衍生物,中文名为(E)-2-(2-(10-正丁基-吩噻嗪3-基)乙烯基)-1,1,3-三甲基-1H-苯并[e]吲哚-3-碘化盐,英文名为(E)-2-(2-(10-butyl-10H-phenothiazin-3-yl)vinyl)-1,1,3-trimethyl-1H-benzo[e]indol-3-ium,命名为PTBI,结构式如下:
。
本发明提供的苯并吲哚盐-吩噻嗪衍生物的合成方法,包括以下步骤:
(1)冰浴条件下,将氢化钠加入吩噻嗪的N,N-二甲基甲酰胺溶液中,于常温下反应0.5~1.5h后将溴丁烷滴加至该反应体系中,在65~75℃下反应2~4 h,反应结束后将其冷却至室温,加冰水淬灭反应,乙酸乙酯萃取,收集有机相并用无水硫酸钠干燥,减压旋干,柱层析分离提纯得10-正丁基吩噻嗪。其中,吩噻嗪与氢化钠的摩尔比为1:2~1:4;吩噻嗪与溴丁烷的摩尔比为1:1~1:2;柱层析分离洗脱剂为石油醚。
(2)氩气氛围和冰浴条件下,将N,N-二甲基甲酰胺加入三氯氧磷中,于冰浴下反应15~20 min,随后将10-正丁基吩噻嗪的DMF溶液滴加至该反应混合物中,于55~65℃油浴反应3~4h,反应结束后将其冷却至室温并倒入冰水中,用饱和碳酸氢钠中和,二氯甲烷萃取,有机相用无水硫酸钠干燥,减压旋干并柱层析分离提纯得10-正丁基吩噻嗪-3-甲醛。其中,三氯氧磷和N,N-二甲基甲酰胺的摩尔比为1:1~1:2;10-正丁基吩噻嗪与三氯氧磷的摩尔比为1:3~1:5;柱层析分离洗脱剂为石油醚:乙酸乙酯 =20:1。
(3)将1,1,2-三甲基苯-1H-苯并[e]吲哚溶于乙腈中,将碘甲烷加入该反应体系,于65~75℃下回流反应10~12h,反应结束后将反应体系冷却至室温,将得到的沉淀抽滤,洗涤,得到1,1,2,3-四甲基苯-1H-苯并[e]吲哚-3-碘化盐。其中,1,1,2-三甲基苯-1H-苯并[e]吲哚与碘甲烷的摩尔比为1:2~1:3。
(4)将10-正丁基吩噻嗪-3-甲醛和1,1,2,3-四甲基苯-1H-苯并[e]吲哚-3-碘化盐溶于乙醇中,加入哌啶,于80~90℃加热回流反应10~12h,反应结束后,减压旋干溶剂,柱层析分离提纯得目标产物苯并吲哚盐-吩噻嗪衍生物。其中,10-正丁基吩噻嗪-3-甲醛和1,1,2,3-四甲基苯-1H-苯并[e]吲哚-3-碘化盐的摩尔比为1:1~1:2;10-正丁基吩噻嗪-3-甲醛与哌啶的摩尔比1:1~1:2;柱层析分离洗脱剂为二氯甲烷:乙醇 = 50:1。
苯并吲哚盐-吩噻嗪衍生物PTBI氢谱谱图如图1、碳谱谱图如图2、高分辨质谱谱图如图3。
二、苯并吲哚盐-吩噻嗪衍生物PTBI在水相体系中检测HClO
1、PTBI对HClO的选择性检测
配置初浓度为3 mM的PTBI,30 mM的活性氧、活性氮、氨基酸、阴离子和阳离子溶液。向荧光比色皿中加入2.98mLPBS缓冲液(pH = 7.4,含10%乙腈)和10 μL PTBI,再分别加入10 μL各种分析物,测定490-800 nm(λex= 465 nm)波长范围内的荧光光谱,并建立590 nm处荧光强度与不同物质间的柱状图,图4中1-28号分别是HClO, ONOO-, HO•,1O2, H2O2, O2 −•,t-BuOOH, NO, Cys, Hcy, GSH, L-Ser, DL-Met, L-Phe, L-Lys, L-Leu, L-Pro, L-His, S2-, NO3 -, NO2 -, OAc-, SO4 2-, PO4 3-, K+, Zn2+, Cu2+, Na+。如图4所示,只有HClO的加入可以使PTBI在590 nm处的荧光强度显著增强,其它各种分析物均不能引起PTBI在590nm处荧光信号的改变。因此,PTBI能够实现对HClO的选择性检测。
2、PTBI对不同浓度次氯酸的响应性
配置初浓度为3mM的PTBI,分别向荧光比色皿中加入2.98 mL PBS缓冲液(pH =7.4,含10%乙腈)、10 μLPTBI和10 μL不同浓度的次氯酸,混合均匀后立即用荧光分光光度计测定490-800 nm范围内荧光光谱的变化(λex= 465 nm,λem= 590 nm),结果如图5所示。从图5中的A可以得出,PTBI分子本身在590 nm处几乎没有荧光发射,随着HClO浓度依次增加,590 nm波长处的荧光强度逐渐增强,这说明本发明所提供的PTBI能够超灵敏响应HClO,并且表现出“turn-on”型荧光响应。
以次氯酸浓度为横坐标,590 nm波长下的荧光强度为纵坐标得到次氯酸浓度在0~5μM范围内的线性方程Y = 47.057x + 101.445,其线性相关系数为0.995(图5中的B),通过计算得到PTBI对HClO的检测限为46.5 nM,这表明PTBI对次氯酸的检测具有非常高的灵敏度。
三、苯并吲哚盐-吩噻嗪衍生物PTBI在水相体系中检测SO2
1、PTBI对SO2的选择性检测
配置初浓度为3 mM的PTBI,30 mM的各种分析物,包括活性氧、活性氮、氨基酸、阴离子和阳离子溶液。向荧光比色皿中加入2.98mLPBS缓冲液(pH = 7.4,含10%乙腈)和10 μLPTBI,再分别加入10 μL分析物,测定350-620 nm(λex= 325 nm)波长范围内的荧光光谱,并建立475 nm处荧光强度与不同物质间的柱状图,图6中1-28号分别是HSO3 -,ONOO-,HO•,1O2,H2O2, O2 −•,t-BuOOH, NO, Cys, Hcy, GSH, L-Ser, DL-Met, L-Phe, L-Lys, L-Leu, L-Pro, L-His,S2-, NO3 -, NO2 -, OAc-, SO4 2-, PO4 3-, K+, Zn2+, Cu2+, Na+。如图6所示,只有HSO3 -的加入可以使PTBI在475 nm处的荧光强度显著增强,其它活性氧、活性氮、氨基酸、阴离子和阳离子均不能引起PTBI 475 nm处荧光信号的改变,特别是亲核性离子S2-对HSO3 -的检测没有任何影响。因此,PTBI能够实现对SO2的选择性检测。
2、PTBI对不同浓度亚硫酸氢钠的响应性
配置初浓度为3 mM的PTBI,分别向荧光比色皿中加入2.98 mL PBS缓冲液(pH =7.4,含10%乙腈)、10 μLPTBI和10 μL不同浓度的亚硫酸氢钠,混合均匀并反应1min后,测定350-620nm范围内荧光光谱的变化(λex= 325 nm,λem= 475 nm),结果如图7所示。从图7中的A可以得出,PTBI分子本身在475 nm处几乎没有荧光发射,随着亚硫酸氢钠浓度的增加,475nm处的荧光强度逐渐增强,这说明PTBI能够高效地响应SO2。
以亚硫酸氢钠浓度为横坐标,475 nm波长下的荧光强度为纵坐标得到亚硫酸氢钠浓度在0~14 μM范围内的线性方程Y = 71.44x + 193.742(图7中的B),通过计算得PTBI对亚硫酸氢钠的检测限为52.9nM,这表明PTBI对SO2的检测具有很好的灵敏度。
四、机理分析
本发明苯并吲哚盐-吩噻嗪衍生物由吩噻嗪和苯并吲哚盐共轭连接组成,其中吩噻嗪骨架中的硫原子能够被HClO专一地氧化为亚砜结构,并在590 nm处表现出强的荧光发射,从而实现对HClO的选择性检测;苯并吲哚盐单元的强拉电子作用,易与亲核性的SO2发生Michael加成反应,破坏分子的共轭结构,并在475 nm处出现强的荧光发射,实现了对SO2的选择性检测。
五、苯并吲哚盐-吩噻嗪衍生物PTBI检测细胞内HClO和SO2的应用
1、PTBI的线粒体靶向能力
将处于对数期生长的HeLa接种于六孔板内,于37℃培养箱(含5% CO2)培养过夜后更换新鲜培养基,用HClO(200 μM)和PTBI(5μM)孵育细胞30min,再与市售的线粒体绿色染料Mito-tracker Green(500 nM)孵育细胞30min,随后PBS缓冲液清洗细胞3次,用荧光显微镜进行细胞成像。实验结果如图8所示,PTBI的红色荧光与Mito-tracker Green的绿色荧光完全重叠,说明PTBI能够有效定位至线粒体内。
2、PTBI对细胞内HClO和SO2的检测
将处于对数期生长的HeLa接种于六孔板内,于37℃培养箱(含5% CO2)培养过夜后更换新鲜培养基,分别用(A)PTBI(5μM)孵育细胞30min;(B)HClO(200 μM)孵育细胞30 min,再加入PTBI(5μM)孵育细胞30 min;(C)HSO3 -(200 μM)孵育细胞30 min,再加入PTBI(5μM)孵育细胞30 min;随后PBS缓冲液清洗细胞3次,用荧光显微镜观测红色和蓝色通道荧光信号的变化,结果如图9所示。从图9可以得出,PTBI单独孵育HeLa细胞后,红色和蓝色通道出现较弱的荧光信号,当分别用HClO和HSO3 -孵育细胞后,红色和蓝色通道的荧光均明显增强,这说明本发明所提供的PTBI能够实现对细胞内HClO和SO2的检测。
3、PTBI监测HClO/SO2诱导的线粒体应激及其动态平衡
将处于对数期生长的HeLa细胞接种于六孔板内,于37℃培养箱(含5% CO2)培养过夜后更换新鲜培养基,分别用(A)PTBI(5μM)孵育细胞30 min;(B)NaHSO3(400 μM)孵育细胞1 h,PTBI(5μM)孵育细胞30 min;(C)HClO(400 μM)孵育细胞1 h,PTBI(5μM)孵育细胞30min;随后PBS缓冲液清洗细胞3次,用荧光显微镜观测蓝色和红色通道荧光信号的变化,结果如图10所示。从图10可以得出,当用NaHSO3孵育细胞后,蓝色通道的荧光相比于PTBI单独孵育组明显增强,而且红色通道的荧光也显著增强,这说明该过程中产生了HClO。该结果表明过量SO2诱导的线粒体应激能够促进HClO的产生。当用HClO孵育细胞后,红色通道的荧光明显增强,同时蓝色通道的荧光也轻微增强,说明该过程中产生了SO2。该结果表明过量HClO能够诱导线粒体氧化应激,并伴随着抗氧化剂SO2的产生,以减轻对细胞的氧化损伤。
4、PTBI监测斑马鱼体内HClO和SO2的动力学相互作用
将脱卵培养5天的斑马鱼分为六组,分别放入六孔板中。(A)PTBI(5 μM)孵育斑马鱼30 min;(B)HClO(400 μM)孵育斑马鱼1h,PTBI(5 μM)孵育斑马鱼30 min;(C)LPS(1 μg/mL)孵育斑马鱼30min,PTBI(5 μM)孵育斑马鱼30 min;(D)NaHSO3(400 μM)孵育斑马鱼1h,PTBI(5 μM)孵育斑马鱼30 min;然后用培养液清洗斑马鱼3次,麻醉剂将其麻醉后,荧光显微镜下成像,结果如图11所示。由图11可以看出,PTBI处理斑马鱼后,红色和蓝色通道呈现出微弱的荧光信号,当用HClO和LPS孵育斑马鱼后,红色通道的荧光显著增强,同时蓝色通道的荧光信号也轻微增强,说明过量HClO诱导的应激反应可导致体内抗氧化剂SO2的产生,以维持其氧化还原稳态。当用NaHSO3孵育斑马鱼后,观测到蓝色通道荧光增强,但红色通道的荧光几乎消失,这说明SO2作为抗氧化剂能够清除体内的HClO。
综上所述,本发明与现有技术相比具有以下优点和效果:
本发明提供的苯并吲哚盐-吩噻嗪衍生物PTBI合成便捷,由便宜易得的原料吩噻嗪和苯并吲哚衍生物经四步反应得到,PTBI具有双反应位点、检测灵敏度高和斯托克斯位移大的优势,对HClO和SO2的检测具有高度的选择性,且两者的荧光检测信号互不干扰。该探针分子不仅能够监测胞内的HClO和SO2,同时能够监测HClO和SO2诱导的线粒体应激及其动力学平衡,该探针还实现了监测斑马鱼体内HClO和SO2的动力学相互作用,并阐明了细胞水平和斑马鱼中HClO和SO2所扮演的生理角色。因此,该苯并吲哚盐-吩噻嗪衍生物对相关疾病的诊断和治疗具有重要意义。
附图说明
图1是苯并吲哚盐-吩噻嗪衍生物的1H NMR图谱;
图2是苯并吲哚盐-吩噻嗪衍生物的13C NMR图谱;
图3是苯并吲哚盐-吩噻嗪衍生物的高分辨质谱图;
图4是苯并吲哚盐-吩噻嗪衍生物选择性检测次氯酸的荧光光谱图;
图5是苯并吲哚盐-吩噻嗪衍生物在不同浓度次氯酸条件下的荧光光谱图;
图6是苯并吲哚盐-吩噻嗪衍生物选择性检测二氧化硫的荧光光谱图;
图7是苯并吲哚盐-吩噻嗪衍生物在不同浓度亚硫酸氢钠条件下的荧光光谱图;
图8是苯并吲哚盐-吩噻嗪衍生物靶向线粒体的荧光成像;
图9是苯并吲哚盐-吩噻嗪衍生物检测细胞内次氯酸和二氧化硫的荧光成像;
图10是苯并吲哚盐-吩噻嗪衍生物检测次氯酸和二氧化硫诱导的线粒体应激及其动力学平衡的荧光成像;
图11是苯并吲哚盐-吩噻嗪衍生物检测斑马鱼体内次氯酸和二氧化硫的动力学相互作用的荧光成像。
具体实施方式
下面结合实施例和附图对本发明做进一步说明。
实施例1 苯并吲哚盐-吩噻嗪衍生物的合成
(1)10-正丁基吩噻嗪的合成
冰浴条件下,将氢化钠(45mmol,1.08g)慢慢加入吩噻嗪(15mmol,3g)的N,N-二甲基甲酰胺(10mL)中,将该反应体系于常温反应1h后,再将溴丁烷(18mmol,2mL)慢慢滴加至上述反应体系,随后在70℃反应3 h后将其冷却至室温,慢慢加冰水淬灭,乙酸乙酯萃取,收集有机相并用无水硫酸钠干燥,减压除去有机溶剂,所得样品经柱层析分离(石油醚为洗脱剂)得无色油状液体10-正丁基吩噻嗪(化合物1),产率86%。
(2)10-正丁基吩噻嗪-3-甲醛的合成:
氩气氛围和冰浴条件下,将DMF(6mmol,0.464mL)加入POCl3(6mmol,0.559mL)中,得到的反应体系于冰浴下反应15min后,将化合物1(2mmol,0.57mg)的DMF(2mL)溶液慢慢滴加至上述反应体系中,随后于60℃反应4 h,将反应体系冷却至室温后,倒入冰水中,饱和碳酸氢钠中和,二氯甲烷萃取,有机相用无水硫酸钠干燥,减压除去有机溶剂,所得样品经柱层析分离(石油醚:乙酸乙酯 = 20:1)得黄色固体10-正丁基吩噻嗪-3-甲醛(化合物2),产率75%。
(3)1,1,2,3-四甲基苯-1H-苯并[e]吲哚-3-碘化盐的合成:
将1,1,2-三甲基苯-1H-苯并[e]吲哚(5mmol,1.046g)溶于乙腈(10mL)中,加入碘甲烷(10mmol,0.62mL),将反应体系于70℃回流12h后,冷却至室温,将得到的沉淀抽滤,乙腈洗涤,干燥得白色固体1,1,2,3-四甲基苯-1H-苯并[e]吲哚-3-碘化盐(化合物3)。
(4)PTBI的合成:
将化合物2(1mmol,283mg)和化合物3(1mmol,224mg)溶于乙醇(5mL)中,再将哌啶(50 μL)加入反应混合物中,于85℃回流反应12h后,减压除去有机溶剂,所得样品经柱层析分离(二氯甲烷:乙醇 =50:1)得深蓝色固体的目标产物PTBI,产率71%。
其氢谱谱图如图1:1H NMR(400 MHz, DMSO-d6) δ 8.41 (d,J= 3.6 Hz, 1H),8.38 (d,J= 11.6 Hz, 1H), 8.27 (d,J= 9.2 Hz, 1H), 8.20 (d,J= 8.0 Hz, 1H), 8.11– 8.05 (m, 3H), 7.79 (t,J= 7.8 Hz, 1H), 7.70 (t,J= 7.6 Hz, 1H), 7.56 (d,J=16.4 Hz, 1H), 7.25 (t,J= 7.8 Hz, 1H), 7.19 (d,J= 8.4 Hz, 2H), 7.13 (d,J= 8.0Hz, 1H), 7.03 (t,J= 7.6 Hz, 1H), 4.24 (s, 3H), 4.01 (t,J= 7.0 Hz, 2H), 1.99(s, 6H), 1.74 – 1.64 (m, 2H), 1.48 – 1.38 (m, 2H), 0.90 (t,J= 7.2 Hz, 3H).
其碳谱谱图如图2:13C NMR(101 MHz, DMSO-d6) δ 181.31, 150.28, 148.54,142.10, 137.07, 132.47, 131.56, 130.24, 129.48, 128.38, 127.82, 127.59,127.51, 126.75,126.39, 126.16, 123.21, 123.05, 122.56, 121.65, 116.12,115.20, 112.64, 109.33, 98.99, 52.88, 46.19, 34.17, 27.77, 24.79, 18.74,13.08.
其高分辨质谱谱图如图3:HRMS (ESI) m/z calcd for C33H33N2S (M):489.2359. Found: 489.2355, error: 0.8 ppm.
实施例2、苯并吲哚盐-吩噻嗪衍生物PTBI对HClO的检测
向荧光比色皿中加入2.98mL PBS缓冲液(pH = 7.4,含10%乙腈)和10 μLPTBI(3mM),再分别加入10 μLHClO, ONOO-, HO•,1O2, H2O2, O2 −•,t-BuOOH, NO, Cys, Hcy, GSH,L-Ser, DL-Met, L-Phe, L-Lys, L-Leu, L-Pro, L-His, S2-, NO3 -, NO2 -, OAc-, SO4 2-,PO4 3-, K+, Zn2+, Cu2+, Na+(30 mM)。若PTBI的PBS缓冲液在590 nm处的荧光强度显著增强,说明加入的是HClO;若PTBI的PBS缓冲液在590 nm处的荧光强度没有发生明显变化,说明加入的不是HClO。
实施例3、苯并吲哚盐-吩噻嗪衍生物PTBI对SO2的检测
向荧光比色皿中加入2.98mLPBS缓冲液(pH = 7.4,含10%乙腈)和10 μLPTBI(3mM),再分别加入10 μLHSO3 -, ONOO-,HO•,1O2, H2O2, O2 −•,t-BuOOH, NO, Cys, Hcy, GSH,L-Ser, DL-Met, L-Phe, L-Lys, L-Leu, L-Pro, L-His,S2-, NO3 -, NO2 -, OAc-, SO4 2-,PO4 3-, K+, Zn2+, Cu2+, Na+(30 mM)。若PTBI的PBS缓冲液在475 nm处的荧光强度显著增强,说明加入的是HSO3 -;若PTBI的PBS缓冲液在475 nm处的荧光强度没有发生明显变化,说明加入的不是HSO3 -。
Claims (6)
1.一种苯并吲哚盐-吩噻嗪衍生物,其结构式如下:
。
2.如权利要求1所述的一种苯并吲哚盐-吩噻嗪衍生物的合成方法,包括如下步骤:
(1)冰浴条件下,将氢化钠加入吩噻嗪的N,N-二甲基甲酰胺溶液中,于常温下反应0.5~1.5h后将溴丁烷滴加至该反应体系中,在65~75℃下反应2~4 h,反应结束后将其冷却至室温,加冰水淬灭反应,乙酸乙酯萃取,收集有机相并用无水硫酸钠干燥,减压旋干,柱层析分离提纯得10-正丁基吩噻嗪;吩噻嗪与氢化钠的摩尔比为1:2~1:4;吩噻嗪与溴丁烷的摩尔比为1:1~1:2;
(2)氩气氛围和冰浴条件下,将N,N-二甲基甲酰胺加入三氯氧磷中,于冰浴下反应15~20 min,随后将10-正丁基吩噻嗪的DMF溶液滴加至该反应混合物中,于55~65℃油浴反应3~4h,反应结束后将其冷却至室温并倒入冰水中,用饱和碳酸氢钠中和,二氯甲烷萃取,有机相用无水硫酸钠干燥,减压旋干并柱层析分离提纯得10-正丁基吩噻嗪-3-甲醛;
(3)将1,1,2-三甲基苯-1H-苯并[e]吲哚溶于乙腈中,加入碘甲烷,于65~75℃下回流反应10~12h,反应结束后将反应体系冷却至室温,将得到的沉淀抽滤,洗涤,得到1,1,2,3-四甲基苯-1H-苯并[e]吲哚-3-碘化盐;三氯氧磷和N,N-二甲基甲酰胺的摩尔比为1:1~1:2;10-正丁基吩噻嗪与三氯氧磷的摩尔比为1:3~1:5;1,1,2-三甲基苯-1H-苯并[e]吲哚与碘甲烷的摩尔比为1:2~1:3;
(4)将10-正丁基吩噻嗪-3-甲醛和1,1,2,3-四甲基苯-1H-苯并[e]吲哚-3-碘化盐溶于乙醇中,加入哌啶,于80~90℃加热回流反应10~12h,反应结束后,减压旋干溶剂,柱层析分离提纯得目标产物苯并吲哚盐-吩噻嗪衍生物;10-正丁基吩噻嗪-3-甲醛和1,1,2,3-四甲基苯-1H-苯并[e]吲哚-3-碘化盐的摩尔比为1:1~1:2;10-正丁基吩噻嗪-3-甲醛与哌啶的摩尔比1:1~1:2。
3.如权利要求1所述的苯并吲哚盐-吩噻嗪衍生物在水相体系中检测HClO的应用,其特征在于:在苯并吲哚盐-吩噻嗪衍生物的PBS缓冲液中,分别加入HClO, ONOO-, HO•, 1O2,H2O2, O2 −•, t-BuOOH, NO, Cys, Hcy, GSH, L-Ser, DL-Met, L-Phe, L-Lys, L-Leu, L-Pro, L-His, S2-, NO3 -, NO2 -, OAc-, SO4 2-, PO4 3-, K+, Zn2+, Cu2+, Na+,只有HClO能够使苯并吲哚盐-吩噻嗪衍生物的PBS缓冲液在590 nm处的荧光强度显著增强;PBS缓冲液中,乙腈的体积分数为10%,pH = 7.4。
4.如权利要求1所述的苯并吲哚盐-吩噻嗪衍生物在水相体系中检测SO2的应用,其特征在于:在苯并吲哚盐-吩噻嗪衍生物的PBS缓冲液中,分别加入HSO3 -,ONOO-,HO•, 1O2, H2O2,O2 −•,t-BuOOH, NO, Cys, Hcy, GSH, L-Ser, DL-Met, L-Phe, L-Lys, L-Leu, L-Pro, L-His,S2-, NO3 -, NO2 -, OAc-, SO4 2-, PO4 3-, K+, Zn2+, Cu2+, Na+,只有HSO3 -能够使苯并吲哚盐-吩噻嗪衍生物的PBS缓冲液在475 nm处的荧光强度显著增强;PBS缓冲液中,乙腈的体积分数为10%,pH = 7.4。
5.如权利要求1所述的苯并吲哚盐-吩噻嗪衍生物以非诊断或治疗为目的在细胞中检测HClO的应用。
6.如权利要求1所述的苯并吲哚盐-吩噻嗪衍生物以非诊断或治疗为目的在细胞中检测SO2的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110150987.5A CN112694471B (zh) | 2021-02-04 | 2021-02-04 | 一种苯并吲哚盐-吩噻嗪衍生物及其制备和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110150987.5A CN112694471B (zh) | 2021-02-04 | 2021-02-04 | 一种苯并吲哚盐-吩噻嗪衍生物及其制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112694471A CN112694471A (zh) | 2021-04-23 |
CN112694471B true CN112694471B (zh) | 2023-10-24 |
Family
ID=75516602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110150987.5A Active CN112694471B (zh) | 2021-02-04 | 2021-02-04 | 一种苯并吲哚盐-吩噻嗪衍生物及其制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112694471B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114195774B (zh) * | 2021-11-04 | 2023-09-26 | 徐州医科大学 | 一种具有次氯酸激活荧光和线粒体靶向功能的光敏剂及其制备方法和应用 |
CN115181098B (zh) * | 2022-04-27 | 2023-04-07 | 武汉工程大学 | 一种靶向线粒体的aie型次氯酸荧光探针及其制备方法、应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110128371A (zh) * | 2019-04-24 | 2019-08-16 | 中国科学院上海微系统与信息技术研究所 | 一种吩噻嗪苯甲醛衍生物及其制备方法,吩噻嗪喹啉分子荧光探针及其制备方法和应用 |
CN111732581A (zh) * | 2020-06-29 | 2020-10-02 | 太原师范学院 | 一种检测次氯酸/次氯酸钠的荧光探针及制备方法和应用 |
-
2021
- 2021-02-04 CN CN202110150987.5A patent/CN112694471B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110128371A (zh) * | 2019-04-24 | 2019-08-16 | 中国科学院上海微系统与信息技术研究所 | 一种吩噻嗪苯甲醛衍生物及其制备方法,吩噻嗪喹啉分子荧光探针及其制备方法和应用 |
CN111732581A (zh) * | 2020-06-29 | 2020-10-02 | 太原师范学院 | 一种检测次氯酸/次氯酸钠的荧光探针及制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112694471A (zh) | 2021-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108484622B (zh) | 多信号荧光探针的合成及其同时区分检测Hcy、Cys和GSH的应用 | |
Dong et al. | A novel ferrocenyl-based multichannel probe for colorimetric detection of Cu (II) and reversible fluorescent “turn-on” recognition of Hg (II) in aqueous environment and living cells | |
CN112694471B (zh) | 一种苯并吲哚盐-吩噻嗪衍生物及其制备和应用 | |
Gong et al. | A novel two-photon fluorescent probe with long-wavelength emission for monitoring HClO in living cells and tissues | |
US10351707B2 (en) | Water-soluble iron ion fluorescent probe and preparation method thereof | |
CN109336815B (zh) | 一种检测细胞内质网内次氯酸的双光子荧光探针 | |
CN104419401A (zh) | 一种荧光增强检测硫化氢荧光探针及其合成与应用 | |
CN113501818B (zh) | 一种荧光探针分子及其制备方法与应用 | |
CN110526908B (zh) | 基于2-苯乙烯基吲哚盐类衍生物长波发射可区分检测Cys/Hcy荧光探针及其应用 | |
CN109180716B (zh) | 一种多信号比率型区分检测h2o2和h2s的荧光探针的设计、合成及应用 | |
CN109928940B (zh) | 基于碱性蓝-3的检测次氯酸的近红外荧光探针分子的制备 | |
CN113004258A (zh) | 一种基于esipt效应的硫化氢比率型荧光分子探针的制备方法及其应用 | |
CN103382189A (zh) | 一类菁类化合物、其制备方法及应用 | |
CN111778014A (zh) | β-半乳糖苷酶近红外荧光探针及其制备方法和用途 | |
CN114539222A (zh) | 一种七甲川菁-萘酰亚胺杂合体的合成和作为近红外荧光探针在检测谷胱甘肽中的应用 | |
CN107501221B (zh) | 一种对生物体内硫化氢快速响应的荧光探针及其制备方法和用途 | |
CN110655510B (zh) | 一种靶向脂滴的亚硫酸盐比率荧光探针及其应用 | |
CN113637048A (zh) | 一种γ-谷氨酰转肽酶的双光子荧光探针及其制备方法和应用 | |
CN117164575A (zh) | 一种单激发检测onoo-的近红外比率荧光探针及其制备方法和应用 | |
CN109608495B (zh) | 一种检测hno的化合物及其制备方法和应用 | |
CN111393401A (zh) | 一种基于罗丹明衍生物检测心肌黄酶的荧光探针分子及制备方法和用途 | |
CN112358475B (zh) | 一种苯并吡喃鎓-吩噻嗪衍生物及其制备方法和应用 | |
CN114736199B (zh) | 一种基于亚甲基蓝的近红外荧光探针及其合成方法和应用 | |
CN111635385B (zh) | 一种线粒体靶向的双光子激发近红外发射的硫化氢荧光探针及其制备方法和应用 | |
CN108218817A (zh) | 一种区分GSH、Cys、SO2荧光探针及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |